Oncology

Biomarker-directed regimens in cancer not only ensure treatment for the right patient population, it also makes economic sense, especially in today's climate of high-cost specialty medications like the novel immunooncology agents, nivolumab and pembrolizumab.

Anju Nohria, MD, assistant professor, Harvard Medical School, spoke to Evidence-Based Oncology about some of the challenges clinicians face with monitoring cardiovascular risks in cancer patients.

A Cardio-Oncology Working Group formed by the ACC conducted a nationwide survey focused on cardio-oncology services, gathering opinions from cardiovascular division chiefs and fellowship training directors. This helped identify important challenges, including the need for broader educational opportunities and training.

The American Journal of Managed Care convened experts in health policy, from health plans, and from community oncology, to discuss OCM and other issues in oncology care during the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

To discuss patient-reported outcomes and their importance in patient-centered care, The American Journal of Managed Care convened a panel of healthcare experts to participate in the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

Luis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1.

Much-anticipated trial results were presented on the third day of the annual meeting of the American Society of Clinical Oncology, held in Chicago. These included phase 3 results from the CheckMate 067 trial and a phase 2 study with elotuzumab.

While the clinical data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) created waves, a session on value had an equally significant impact as oncologists thronged to hear stakeholder voices define this, as yet abstract, concept of "value" in cancer care. The session brought together a patient representative, an oncologist, an ASCO representative, and a payer.

The Patient Advocate Program (PAF) serves patients with chronic, life threatening or debilitating diseases by providing direct financial support as well as case management support. Alan Balch, PhD, chief executive officer, PAF, explained that PAF guides their members through insurance systems when issues of access or affordability arise for the individual.

A late-breaking abstract session early on the second day of the annual meeting of the American Society of Clinical Oncology was reserved for the latest data from clinical trials evaluating the new immuno-oncology agents of the PD-1 inhibitor class.

Supporting shared decision making between cancer patients and oncologists starts with an understanding of what the physician's role is, explained Peter P. Yu, MD, FACP, FASCP, president of the American Society of Clinical Oncology and director of cancer research at Palo Alto Medical Foundation.

During the Health Services Research and Quality of Care session on the second day of the annual meeting of the American Society of Clinical Oncology, being held at the McCormick Convention Center, Chicago, oncologists discussed barriers to patient participation in cancer clinical trials, and discussed attributes of the high cost of care.

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.

This week CMS unveiled its proposed rule to overhaul Medicaid managed care and folded to Florida Governor Rick Scott, and the American Society of Clinical Oncology kicks off its annual meeting in Chicago.

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD.

The move to have patients shoulder greater share of their cost of care is particularly challenging in cancer care, according to Jennifer Malin, MD, medical director for oncology at Anthem.

On the first day at the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some of the newer agents currently available to treat lymphoma and described their experience with these agents during the session, "Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday Practice."

More than half of women diagnosed with breast cancer undergo breast-conserving surgery with a partial mastectomy. A new study from the Yale Cancer Center found that removing more tissue during this procedure could spare thousands of these patients from a second surgery.

An international study has estimated that in 2013, there were 14.9 million newly diagnosed cases of cancer and 8.2 million deaths around the world.

Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.

Cancer patients under the age of 65 are much more likely to try alternative and complimentary medicine to ease their symptoms and the side effects of their cancer treatments.

A study published in the New England Journals of Medicine evaluated the ability of financial incentives in promoting smoking cessation.

With more than 35,000 people expected to attend the 2015 ASCO Annual Meeting, there are many highly anticipated aspects of the conference; however, Peter P. Yu, MD, FACP, FASCO, president of ASCO and director of Cancer Research at Palo Alto Medical Foundation, highlighted how the society has been going in a different direction with its keynote speaker.

Medical monitoring and counseling can help us track and contain many harmful effects of cancer drug-induced cardiotoxicity. Patient engagement from the very beginning, along with medically advanced testing methods, can help us surmount cardiotoxicity and better ensure that patients receive only the benefits of essential cancer treatment.

Improved survivorship rates among cancer patients has brought a growing awareness of a serious latent impact of chemotherapy and radiation: cardiotoxicity. Despite extensive research on the subject, our understanding of the tools for identifying and preventing these complications is limited.